CN102844301B - 新苯甲酰胺衍生物 - Google Patents

新苯甲酰胺衍生物 Download PDF

Info

Publication number
CN102844301B
CN102844301B CN201180020476.6A CN201180020476A CN102844301B CN 102844301 B CN102844301 B CN 102844301B CN 201180020476 A CN201180020476 A CN 201180020476A CN 102844301 B CN102844301 B CN 102844301B
Authority
CN
China
Prior art keywords
methyl
formula
chloro
piperidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180020476.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102844301A (zh
Inventor
金舜会
任元彬
崔成鹤
崔善镐
孙铸姬
成铉贞
金敉延
赵康勋
孙兑炅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East-Asia Pharmaceutical Co Ltd
Original Assignee
East-Asia Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East-Asia Pharmaceutical Co Ltd filed Critical East-Asia Pharmaceutical Co Ltd
Publication of CN102844301A publication Critical patent/CN102844301A/zh
Application granted granted Critical
Publication of CN102844301B publication Critical patent/CN102844301B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
CN201180020476.6A 2010-04-23 2011-04-18 新苯甲酰胺衍生物 Expired - Fee Related CN102844301B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0038039 2010-04-23
KR1020100038039A KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체
PCT/KR2011/002759 WO2011132901A2 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives

Publications (2)

Publication Number Publication Date
CN102844301A CN102844301A (zh) 2012-12-26
CN102844301B true CN102844301B (zh) 2015-04-22

Family

ID=44834616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180020476.6A Expired - Fee Related CN102844301B (zh) 2010-04-23 2011-04-18 新苯甲酰胺衍生物

Country Status (19)

Country Link
US (1) US9221790B2 (enExample)
EP (1) EP2560955B1 (enExample)
JP (1) JP5564147B2 (enExample)
KR (1) KR101180174B1 (enExample)
CN (1) CN102844301B (enExample)
AU (1) AU2011243393B2 (enExample)
BR (1) BR112012026509B1 (enExample)
CA (1) CA2794176C (enExample)
ES (1) ES2594708T3 (enExample)
IL (1) IL222491A (enExample)
MX (1) MX2012011721A (enExample)
MY (1) MY162554A (enExample)
NZ (1) NZ602612A (enExample)
PH (1) PH12012501843A1 (enExample)
RU (1) RU2536688C2 (enExample)
SG (1) SG184350A1 (enExample)
UA (1) UA107702C2 (enExample)
WO (1) WO2011132901A2 (enExample)
ZA (1) ZA201207903B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
US9771348B2 (en) 2013-07-25 2017-09-26 Dong-A St Co., Ltd Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate
CN104230889A (zh) * 2014-08-29 2014-12-24 南京大学 环丙沙星衍生物及其制备方法与用途
KR102394635B1 (ko) * 2015-03-31 2022-05-09 (주)아모레퍼시픽 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641330A (zh) * 2007-03-16 2010-02-03 东亚制药株式会社 苯甲酰胺衍生物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP0774460A1 (en) 1994-03-30 1997-05-21 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compound and use thereof as medicine
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
KR20010081034A (ko) * 1998-11-20 2001-08-25 프리돌린 클라우스너, 롤란드 비. 보레르 피페리딘 씨씨알-3 수용체 길항제
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
ES2526338T3 (es) 2007-04-19 2015-01-09 Dong-A Pharm.Co., Ltd. Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010062959A1 (en) 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
BR112012023139A2 (pt) 2010-03-24 2018-06-26 Dong A Pharm Co Ltd composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma.
SG190415A1 (en) 2010-11-24 2013-06-28 Dong A St Co Ltd Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
JP5599519B2 (ja) 2010-11-24 2014-10-01 ドン−ア エスティ カンパニー リミテッド キノリン誘導体化合物、その製造方法およびそれを含む薬学組成物
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641330A (zh) * 2007-03-16 2010-02-03 东亚制药株式会社 苯甲酰胺衍生物及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Design and Synthesis of Orally Active Benzamide Derivatives as Potent Serotonin 4 Receptor Agonist;Shuji Sonda et al.;《Bioorganic & Medicinal Chemistry》;20031231;第11卷;4225-4234 *
Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists;Katsuhiko Itoh et al.;《Eur.J.Med.Chem.》;19991231;第34卷;329-341 *

Also Published As

Publication number Publication date
MX2012011721A (es) 2012-12-17
CA2794176C (en) 2015-12-15
RU2536688C2 (ru) 2014-12-27
BR112012026509B1 (pt) 2021-01-19
RU2012150037A (ru) 2014-05-27
KR101180174B1 (ko) 2012-09-05
EP2560955A4 (en) 2013-09-11
US20130085160A1 (en) 2013-04-04
MY162554A (en) 2017-06-15
AU2011243393A1 (en) 2012-10-18
WO2011132901A2 (en) 2011-10-27
AU2011243393B2 (en) 2014-07-17
ZA201207903B (en) 2013-06-26
BR112012026509A2 (pt) 2017-10-31
IL222491A0 (en) 2012-12-31
JP5564147B2 (ja) 2014-07-30
NZ602612A (en) 2014-11-28
SG184350A1 (en) 2012-11-29
CA2794176A1 (en) 2011-10-27
WO2011132901A3 (en) 2012-01-26
PH12012501843A1 (en) 2013-01-07
IL222491A (en) 2016-07-31
EP2560955B1 (en) 2016-06-29
UA107702C2 (xx) 2015-02-10
CN102844301A (zh) 2012-12-26
KR20110118446A (ko) 2011-10-31
JP2013525344A (ja) 2013-06-20
US9221790B2 (en) 2015-12-29
EP2560955A2 (en) 2013-02-27
ES2594708T3 (es) 2016-12-22
HK1176061A1 (en) 2013-07-19

Similar Documents

Publication Publication Date Title
CN102149705B (zh) 作为肥大细胞类胰蛋白酶抑制剂的[4-(5-氨基甲基-2-氟苯基)-哌啶-1-基]-[7-氟-1-(2-甲氧基乙基)-4-三氟甲氧基-1h-吲哚-3-基]-甲酮
CN1481361A (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
JPH10511973A (ja) タキキニンアンタゴニスト活性を有するピペリジン誘導体
CN102844301A (zh) 新苯甲酰胺衍生物
JP6498672B2 (ja) 疼痛に対して多重モードの活性を有するピペリジン化合物
TW200800167A (en) Organic compounds
CA2770766C (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
JP5663743B2 (ja) モチリン受容体作動活性を有するオキシインドール誘導体
CN107074816B (zh) 一种杂环衍生物及其制备方法和在医药上的用途
CN112759544B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途
KR20010031839A (ko) 한 개의 질소원자를 함유하는 5, 6 또는 7원헤테로사이클릭 환으로 치환된 이미다조일알킬
JP2012519153A5 (enExample)
JPH111472A (ja) ベンズアミド誘導体及びそれを含有する医薬組成物
CN112759545A (zh) 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CN112759587A (zh) 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CZ300765B6 (cs) Deriváty (1-fenacyl-3-fenyl-3-piperidylethyl)piperidinu, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
CN112759546B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
HK1176061B (zh) 新苯甲酰胺衍生物
EP3990091A1 (en) Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
JPWO1996038420A1 (ja) 単環系アミンを有するインダゾール誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176061

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1176061

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150422

CF01 Termination of patent right due to non-payment of annual fee